Please turn your Device

We transform immunology into life-changing treatments

Immuno-
Oncology

Immune
Tolerance

Inflammatory
Diseases

Immuno-Oncology Progress: PragmaTIL Trial Receives Approval, with Anaveon as a Key Partner Read more

Pipeline

Discovery

Preclinical

Pre-IND

Phase I

Phase II

CollaboratorsCollab.

ANV600

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer…
> Read more

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors…
> Read more

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study…
> Read more

Anaveon presents new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy…
> Read more

ANV700

Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society…
> Read more

ANV200

undisclosed

About

Meet Our Team

We are a dedicated team of scientists with decades of collective experience in drug development.
Our expertise, curiosity and drive to deliver tangible results set us apart.
We focus on science in order to identify solutions to patient needs.

High-profile investors fund Anaveon

Others share our vision, and international investors have backed Anaveon with funding of more than 146 million CHF (€140 million) since the company’s foundation in 2017.

Investigators

Message to Investigators

Anaveon – Message to Investigators

We are exploiting the power of immunology to orchestrate immune responses by using protein engeneering to create safe and effective treatments for patients with high unmet medical needs.

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com

Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept